Veniti(TM), Inc. (Veniti), has received approval to CE Mark the Veniti Vici(TM) Venous Stent, specifically designed for the treatment of venous obstruction. In addition, the company received CE Mark approval for their varicose vein ablation product, the Veniti Veni(TM) RF Plus Ablation System. The CE Marks allow Veniti to sell products within the European Union.

Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) allowing the company to initiate SYMPLICITY HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in U.S. patients. 

AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced EU CE Mark approval for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit for use during extracorporeal bypass for up to six hours. Under the CE Mark approval the AngioVac cannula is also approved for removal of fresh, soft thrombi or emboli.

Stroke is the second leading cause of death in Los Angeles County and the fourth in the U.S. In order to cut those numbers, it's imperative that new treatments be developed and refined for stroke prevention, acute therapy and recovery after stroke.

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Ostial Corporation to distribute the Flash Ostial System Dual Balloon Angioplasty Catheter in the United States. The Flash Ostial System is designed to help overcome the challenges of aorto-ostial stenting and compliments the Mynx® Product Family of Vascular Closure Devices to expand AccessClosure’s portfolio.

The Cardiovascular Care Group (TCVCG), announced today it has united with The Vein Institute of New Jersey to offer patients access to an expanded team of highly skilled clinicians with outstanding results and additional locations throughout Central and Northern New  Jersey. Reinforcing its commitment to producing great outcomes for the millions of Americans who have varicose and spider veins, the merger increases the number of board–certified physicians available to patients further enabling The Vein Institute at TCVCG to meet the growing demand for its services.

Data from a study led by researchers at Saint Luke's Mid America Heart Institute<http://globalmessaging1.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=7563978&adr_order=59&url=aHR0cDovL3d3dy5zYWludGx1a2VzaGVhbHRoc3lzdGVtLm9yZy9zZXJ2aWNlcy9oZWFydC1hbmQt%0AdmFzY3VsYXItY2FyZGlvdmFzY3VsYXItc2VydmljZXM%3D> showed marked, long-term improvement in health status in patients suffering from peripheral artery disease treated with the S.M.A.R.T. Nitinol Self-Expandable Stent. The study was sponsored by Cordis Corporation, (Fremont, Calif.), manufacturer of the S.M.A.R.T. Stent.

Faced with a disparate array of information technology (IT) products throughout its 19 facilities located in the state of Virginia, Sentara Healthcare selected Medstreaming Vascular Software Solutions and began an enterprise-wide installation late last year. Post-installation, Sentara officials have reported significant efficiency gains in patient throughput, report standardization, quality and workflow.